Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
View original at finance.yahoo.comMerck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide decanoate, Merck’s investigational oral PCSK9 inhibitor, which may help address the cardiovascular (C…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
ASCVD accounts for 85% of CV deaths
60% confidenceNearly 70% of people with ASCVD who are treated with lipid lowering therapies do not reach target LDL cholesterol levels
60% confidenceCpcPH-HFpEF is thought to be uncommon and underdiagnosed, typically impacting people who are older and have other comorbid conditions
60% confidenceBuilding on our history of bringing forward innovative therapies in heart and lung disease, we are proud to share research at ACC.26 that improves our understanding of these serious diseases and has the potential to help patients around the world
60% confidenceThe silent CV epidemic is the leading cause of deaths globally, contributing to the majority of heart attacks and strokes, and deaths related to CV continue to rise
60% confidenceThe data planned for presentation at ACC will underscore the strength and momentum of Merck's cardio-pulmonary pipeline as we work to advance research that helps address the CV epidemic impacting millions with atherosclerosis, as well as CpcPH-HFpEF, a distinct syndrome with limited treatment options
60% confidenceEnlicitide has the potential to be the first approved oral PCSK9 inhibitor
60% confidenceCpcPH-HFpEF is associated with a worse prognosis and higher mortality rate compared to HFpEF alone
60% confidenceThere are no treatments specifically approved for CpcPH-HFpEF
60% confidence